Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab
Thomas E. Delea, Paul Tappenden, Oleg Sofrygin, Dominy Browning, Mayur Mohan Amonkar, Jonathan Karnon, Mel Walker, David Cameron
Research output: Contribution to journal › Article › peer-review
17Citations
(Scopus)
Fingerprint
Dive into the research topics of 'Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab'. Together they form a unique fingerprint.